Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 3NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 22Stomach Neoplasms 3Inflammatory Breast Neoplasms 3Sarcoma 2Ovarian Neoplasms 2Neuroectodermal Tumors, Primitive, Peripheral 2Malignant mesenchymal tumor 2Lymphoma 2Liver Neoplasms 2Liposarcoma 2Hemangiosarcoma 2Hemangiopericytoma, Malignant 2Fibrosarcoma 2Esophageal Neoplasms 2Desmoplastic Small Round Cell Tumor 2Carcinoma, Hepatocellular 2Breast Neoplasms, Male 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Postoperative Complications 1Neoplasms, Unknown Primary 1Lung Neoplasms 1Hodgkin Disease 1Head and Neck Neoplasms 1Fallopian Tube Neoplasms 1Esthesioneuroblastoma, Olfactory 1Endometrial Neoplasms 1

Interventions

Trastuzumab 12Paclitaxel 10Taxes 9Doxorubicin 7Cyclophosphamide 7Docetaxel 6Bevacizumab 6Lapatinib 5Filgrastim 52,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 5Vorinostat 4tipifarnib 3pegfilgrastim 3cediranib 3Peripheral Blood Stem Cell Transplantation 3N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 3Carboplatin 3Capecitabine 3veliparib 2ixabepilone 2entinostat 2alvocidib 2Tamoxifen 2Radiotherapy 2Neoadjuvant Therapy 2MK 2206 2Interleukin-12 Subunit p35 2Interleukin-12 2Immunoenzyme Techniques 2Granulocyte Colony-Stimulating Factor 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Breast Neoplasms, Male × Epirubicin × Clear all
NCT01624441 2018-03-30

Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer

National Cancer Institute (NCI)

Phase 1 Completed
40 enrolled
Breast

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT01093235 2010-03-25

Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer

National Cancer Institute (NCI)

Phase 3 Unknown
800 enrolled
Breast

Breast Neoplasms, Postoperative Complications, Breast Neoplasms, Male, Inflammatory Breast Neoplasms, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡